E2A Monoclonal Antibody

This gene encodes a member of the E protein (class I) family of helix-loop-helix transcription factors. E proteins activate transcription by binding to regulatory E-box sequences on target genes as heterodimers or homodimers, and are inhibited by heterodimerization with inhibitor of DNA-binding (class IV) helix-loop-helix proteins. E proteins play a critical role in lymphopoiesis, and the encoded protein is required for B and T lymphocyte development. Deletion of this gene or diminished activity of the encoded protein may play a role in lymphoid malignancies. This gene is also involved in several chromosomal translocations that are associated with lymphoid malignancies including pre-B-cell acute lymphoblastic leukemia (t(1;19), with PBX1), childhood leukemia (t(19;19), with TFPT) and acute leukemia (t(12;19), with ZNF384). Alternatively spliced transcript variants encoding multiple isoforms have bee

Introducing the E2A Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of immunology. This meticulously engineered antibody showcases unparalleled specificity and affinity, rendering it an indispensable tool for researchers and clinicians alike.

The E2A Monoclonal Antibody boasts an exceptional level of purity, ensuring optimal performance and reproducibility in a wide range of applications. Its unique composition enables precise targeting of the E2A protein, a key regulator of cellular differentiation and development. By selectively binding to this protein, the antibody facilitates the elucidation of intricate molecular mechanisms underlying various physiological and pathological processes.

Crafted with utmost precision, the E2A Monoclonal Antibody exhibits remarkable stability and consistency, guaranteeing reliable results across multiple experiments. Its exceptional sensitivity enables the detection of even the most minute quantities of the E2A protein, empowering researchers to delve deeper into the intricacies of cellular signaling pathways.

Furthermore, the E2A Monoclonal Antibody's versatility extends beyond research laboratories, as it holds immense potential for clinical applications. Its ability to accurately identify aberrant E2A protein expression patterns opens new avenues for diagnostic and prognostic purposes, facilitating personalized treatment strategies for patients.

In summary, the E2A Monoclonal Antibody represents a groundbreaking advancement in the realm of immunology. Its unrivaled specificity, stability, and sensitivity make it an indispensable asset for researchers and clinicians seeking to unravel the complexities of cellular biology and improve patient outcomes. Embrace the future of immunological research and clinical practice with the E2A Monoclonal Antibody.